Vaprisol (conivaptan HCl, from Astellas Pharma) Premixed injection, an arginine vasopressin (AVP) receptor antagonist, is available for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients. Vaprisol Premixed was approved by the FDA in October 2008.

Vaprisol Premixed is available in a 100mL, single-use container containing 20mg of conivaptan HCl in a 5% dextrose solution. The premixed formulation requires no measuring or mixing and has an expiration date of 24 months.

For more information call (800) 727-7003 or visit